Next Article in Journal
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
Next Article in Special Issue
Independent Mechanisms Lead to Genomic Instability in Hodgkin Lymphoma: Microsatellite or Chromosomal Instability
Previous Article in Journal
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
Previous Article in Special Issue
The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma

Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada
Author to whom correspondence should be addressed.
Cancers 2018, 10(6), 204;
Received: 16 May 2018 / Revised: 4 June 2018 / Accepted: 12 June 2018 / Published: 15 June 2018
(This article belongs to the Special Issue Hodgkin's Lymphoma)
Hodgkin Lymphoma (HL) is a unique disease entity both in its pathology and the young patient population that it primarily affects. Although cure rates are high, survivorship can be linked with significant long-term morbidity associated with both chemotherapy and radiotherapy. The most significant recent advances have been with the use of the anti-CD30-drug conjugated antibody brentuximab vedotin (BV) and inhibitors of program death 1 (PD-1). HL is genetically wired to up-regulate program death ligand 1 (PD-L1) in >95% of cases, creating a state of so-called “T cell exhaustion”, which can be reversed with immune checkpoint-inhibitor blockade. The overall and complete response rates to PD-1 inhibitors in patients with relapsed or refractory HL are 70% and 20%, respectively, with a long median duration of response of ~16 months. In fact, PD-1 inhibitors can benefit a wide spectrum of relapsed HL patients, including some who have “progressive disease” by strict response criteria. We review the biology of HL, with a focus on the immune micro-environment and mechanisms of immune evasion. We also provide the rationale supporting the use of PD-1 inhibitors in HL and highlight some of the challenges of monitoring disease response in patients treated with this immunotherapy. View Full-Text
Keywords: Hodgkin Lymphoma; immune checkpoint inhibitors; immunotherapy Hodgkin Lymphoma; immune checkpoint inhibitors; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Meti, N.; Esfahani, K.; Johnson, N.A. The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers 2018, 10, 204.

AMA Style

Meti N, Esfahani K, Johnson NA. The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers. 2018; 10(6):204.

Chicago/Turabian Style

Meti, Nicholas, Khashayar Esfahani, and Nathalie A. Johnson. 2018. "The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma" Cancers 10, no. 6: 204.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop